NCT00429481View on ClinicalTrials.gov

Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

2,464

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

April 30, 2003

Study Completion Date

April 30, 2003

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Rotarix

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00429481 - Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants | Biotech Hunter | Biotech Hunter